Seroprevalence of IgG antibodies to pertussis toxin in the Slovene population

Wiener Klinische Wochenschrift

Volumn 118, Issue 11-12, 2006, Pages 336-340

  Sočan, Maja ^a   Prosenc, Katarina ^a   Vegnuti, Miljana ^a  

^a NATIONAL INSTITUTE OF PUBLIC HEALTH   (Slovenia)

Author keywords

Geometric mean titers; IgG antibodies to pertussis toxin; Pertussis; Seroprevalence

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; PERTUSSIS TOXIN;

ADOLESCENT; ADULT; ARTICLE; BORDETELLA PERTUSSIS; CHILD; CONTROLLED STUDY; FEMALE; GEOMETRY; HUMAN; IMMUNITY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PERTUSSIS; POPULATION RESEARCH; SEROLOGY; SEROPREVALENCE; SLOVENIA; STATISTICAL ANALYSIS; VACCINATION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIBODIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PERTUSSIS TOXIN; PERTUSSIS VACCINE; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SLOVENIA; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 33746357895     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-006-0609-y     Document Type: Article

References (24)

1. Yeh SH (2003) Pertussis: persistent pathogen, imperfect vaccines. Expert Rev Vaccines 2: 113-127
2. Versteegh FG, Mertens PI, de Melker HE, Roord JJ, Schellekens JF, Teunis PF (2005) Age-specific long-term course of IgG antibodies to pertussis toxin after symptomatic infection with Bordetella pertussis. Epidemiol Infect 133: 737-748
3. Cherry JD, Grimpel E, Guiso N, Heininger U, Mertsola J (2005) Defining pertussis epidemiology: clinical, microbiologic and serologic perspectives. Pediatr Infect Dis J 24 [Suppl 5]: S25-S34
4. Wendelboe AM, Van Rie A, Salmaso S, Englund JA (2005) Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 24 [Suppl 5]: S58-S61
5. Mills KHG (2001) Immunity to Bordetella pertussis. Microb Infect 3: 655-657
6. Olin P, Gustafsson L, Barreto L, Hessel L, Mast TC, Van Rie A, et al (2003) Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine 21: 2015-2021
7. Fruhwirth M, Neher C, Schmidt-Schlapfer G, Allerberger F (2002) Bordetella pertussis and Bordetella parapertussis infection in an Austrian pediatric outpatient clinic. Wien Klin Wochenschr 114: 377-382
8. Skladal D, Horak E, Fruhwirth M, Maurer H, Simma B (2004) Successful treatment of ARDS and severe pulmonary hypertension in a child with Bordetella pertussis infection. Wien Klin Wochenschr 116: 760-762
9. Miller E, Fleming DM, Ashworth LAE, Mabbett DA, Vurdien JE, Elliot TSJ (2000) Serological evidence of pertussis in patients presenting with cough in general practice in Birmingham. Commun Dis Public Health 3: 132-134
10. Morgan Mink CA, Cherry JD, Christenson P, Lewis K, Pineda E, Shlian D, et al (1992) A search for Bordetella pertussis infection in university students. Clin Infect Dis 14: 464-411
11. Kraigher A, Sočan M, Kuhelj I, Šmon L (2002) Vaccination and vaccine - guidelines and recommendations (in Slovene). Institute of Public Health, Ljubljana, pp 23-29
12. Kraigher A, Hočevar-Grom A, Klavs I, Sočan M, Vitek-Grgič M, Paragi M, et al (2002) Surveillance of communicable diseases in year 2001 (in Slovene). Zdrav Var 41 [Suppl 4]: 13-15
13. Giammanco A, Chiarini A, Maple PA, Andrews N, Pebody R, Gay N, et al (2003) European Sero Epidemiology Network: standardisation of the assay results for pertussis. Vaccine 22: 112-120
14. Kraigher A, Šmon L, Arhar D, Imenšek Š, Vrbanc A, Plevelj B (2001) The implementation of vaccination programme in Slovenia year 2000 (in Slovene). Zdrav Var 6: 3-31
15. Storsaeter J, Hallander HO, Gustafsson L, Olin P (2003) Low level of pertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine 21: 3542-3549
16. Taranger J, Trollfors B, Lagergard T, Sundh V, Bryla DA, Schneerson R, et al (2000) Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis 181: 1010-1013
17. Giammanco A, Chiarini A, Stroffolini T, de Mattia D, Chiaramonte M, Mochen M, et al (1991) Seroepidemiology of pertussis in Italy. Rev Infect Dis 13: 1216-1220
18. Baughman AL, Bisgard KM, Edwards KM, Guris D, Decker MP, Holland K, et al (2004) Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. Clin Diagn Lab Immunol 11: 1045-1053
19. Cattaneo LA, Reed GW, Haase DH, Wills MJ, Edwards KM (1996) The seroepidemiology of Bordetella pertussis infection: a study of persons ages 1-65 years. J Infect Dis 173: 1256-1259
20. Van der Wielen M, Van Damme P, Van Herck K, Schlegel-Haueter S, Siegrist CA (2003) Seroprevalence of Bordetella pertussis antibodies in Flanders (Belgium). Vaccine 21: 2412-2417
21. Konda T, Kamachi K, Iwaki M, Matsunaga Y (2002) Distribution of pertussis antibodies among different age groups in Japan. Vaccine 20: 1711-1717
22. Garcia-Corbeira P, Dal-Re R, Aguilar L, Garcia-de-Lomas J (2000) Seroepidemiology of Bordetella pertussis infections in the Spanish population: a cross-sectional study. Vaccine 18: 2173-2176
23. Polyzou A, Pournaras S, Dafni U, Sofianou D, Christeli E, Patrinos S, et al (2004) A Sero epidemiology of Bordetella pertussis immune response in a healthy population in northern Greece. J Clin Lab Anal 18: 211-214
24. Pebody RG, Gay NJ, Giammanco A, Baron S, Schellenks J, Tischer A, et al (2005) The seroepidemiology of Bordetella pertussis infection in Western Europe. Epidemiol Infect 133: 159-171